Bringing our CVRM patient-centric strategy to life at the ADA 2018 Scientific Sessions


We are excited to present the latest research from the Company’s Cardiovascular, Renal and Metabolic (CVRM) Therapy Area at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, USA, 22-26 June 2018.

With novel data from our pre-clinical and clinical diabetes portfolio, our presentations at ADA will underscore our commitment to delivering industry-leading science that will help answer important clinical questions related to the global burden of cardiovascular (CV), renal and metabolic (CaReMe) diseases, including data from diverse patient populations around the world.

The science we will be presenting at ADA is a result of us working with leading academic institutions to elucidate the clinical impact that our novel early science compounds and late-stage medicines can have on critical endpoints spanning CaReMe. The purpose of this work is to provide the broader medical community with answers that are grounded in today’s clinical practice.

Through this extensive research, we’re generating credible science in this meaningful way, positioning AstraZeneca at the forefront of the clinical discussion within CaReMe.

Follow us on Twitter at @AstraZeneca and join the conversation using #2018ADA.

 


AstraZeneca at #2018ADA





References

1. Nichols, et al. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care. 2004; 27(8).

2. “Kidney Disease Statistics for the United States.” National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Department of Health and Human Services, 1 Dec. 2016, www.niddk.nih.gov/health-information/health-statistics/kidney-disease.

3. International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation, 2017.

 

Veeva ID: Z4-11184

Date of next review: June 2020